Prakash Lingasamy

Dr. Prakash Lingasamy

Competence Centre on Health Technologies (Estonia), Tartu, Tartumaa, Estonia
+1
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Journal of Controlled Release
Verified
Journal Article
Closed access
PSPille Säälik
Pille Säälik
PLPrakash Lingasamy
Prakash Lingasamy
KTKadri Toome
Kadri Toome
IMIgnacio Mastandrea
Ignacio Mastandrea
LRLiat Rousso-Noori
Liat Rousso-Noori
TTTambet Teesalu
Tambet Teesalu

2 April 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
PLPrakash Lingasamy
Prakash Lingasamy
ATAllan Tobi
Allan Tobi
KKKaarel Kurm
Kaarel Kurm
SKSergei Kopanchuk
Sergei Kopanchuk
ASAleksander Sudakov
Aleksander Sudakov
TTTambet Teesalu
Tambet Teesalu
Extracellular matrix in solid tumors has emerged as a specific, stable, and abundant target for affinity-guided delivery of anticancer drugs. Here we describe the homing peptide that interacts with the C-isoform of Tenascin-C (TNC-C) upregulated in malignant tissues. TNC-C binding PL3 peptide (amino acid sequence: AGRGRLVR) was identified by in vitro biopanning on recombinant TNC-C. Besides TNC-C, PL3 interacts via its C-end Rule (CendR) motif with cell-and tissue penetration receptor neuropilin-1 (NRP-1). Functionalization of iron oxide nanoworms (NWs) and metallic silver nanoparticles (AgNPs) with PL3 peptide increased tropism of systemic nanoparticles towards glioblastoma (GBM) and prostate carcinoma xenograft lesions in nude mice (eight and five-fold respectively). Treatment of glioma-bearing mice with proapoptotic PL3-guided NWs improved the survival of the mice, whereas treatment with untargeted particles had no effect. PL3-coated nanoparticles were found to accumulate in TNC-C and NRP-1-positive areas in clinical tumor samples, suggesting a translational relevance. The systemic tumor-targeting properties and binding of PL3-NPs to the clinical tumor sections, suggest that the PL3 peptide may have applications as a targeting moiety for the selective delivery of imaging and therapeutic agents to solid tumors.

1 October 2019 in Biomaterials
Verified
Journal Article
Open access
PLPrakash Lingasamy
Prakash Lingasamy
ATAllan Tobi
Allan Tobi
MHMaarja Haugas
Maarja Haugas
HHHedi Hunt
Hedi Hunt
PPPäärn Paiste
Päärn Paiste
TTTambet Teesalu
Tambet Teesalu
Oncofetal fibronectin (FN-EDB) and tenascin-C C domain (TNC-C) are nearly absent in extracellular matrix of normal adult tissues but upregulated in malignant tissues. Both FN-EDB and TNC-C are developed as targets of antibody-based therapies. Here we used peptide phage biopanning to identify a novel targeting peptide (PL1, sequence: PPRRGLIKLKTS) that interacts with both FN-EDB and TNC-C. Systemic PL1-functionalized model nanoscale payloads [iron oxide nanoworms (NWs) and metallic silver nanoparticles] homed to glioblastoma (GBM) and prostate carcinoma xenografts, and to non-malignant angiogenic neovessels induced by VEGF-overexpression. Antibody blockage experiments demonstrated that PL1 tumor homing involved interactions with both receptor proteins. Treatment of GBM mice with PL1-targeted model therapeutic nanocarrier (NWs loaded with a proapoptotic peptide) resulted in reduced tumor growth and increased survival, whereas treatment with untargeted particles had no effect. PL1 peptide may have applications as an affinity ligand for delivery of diagnostic and therapeutic compounds to microenvironment of solid tumors.

1 May 2011 in European Journal of Cell Biology
Verified
Journal Article
Closed access
BFBertrand Favre
Bertrand Favre
YSYann Schneider
Yann Schneider
PLPrakash Lingasamy
Prakash Lingasamy
JBJamal-Eddine Bouameur
Jamal-Eddine Bouameur
NBNadja Begré
Nadja Begré
LFLionel Fontao
Lionel Fontao

1 November 2014 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
JBJamal-Eddine Bouameur
Jamal-Eddine Bouameur
BFBertrand Favre
Bertrand Favre
LFLionel Fontao
Lionel Fontao
PLPrakash Lingasamy
Prakash Lingasamy
NBNadja Begré
Nadja Begré
LBLuca Borradori
Luca Borradori

14 June 2025 in Epigenetics & Chromatin
Verified
Journal Article
Open access
PDF file
KSKarishma Sahoo
Karishma Sahoo
PLPrakash Lingasamy
Prakash Lingasamy
MKMasuma Khatun
Masuma Khatun
SSSajitha Lulu Sudhakaran
Sajitha Lulu Sudhakaran
ASAndres Salumets
Andres Salumets
VMVijayachitra Modhukur
Vijayachitra Modhukur
DNA methylation is a fundamental epigenetic modification that regulates gene expression and maintains genomic stability. Consequently, DNA methylation remains a key biomarker in cancer research, playing a vital role in diagnosis, prognosis, and tailored treatment strategies. Aberrant methylation patterns enable early cancer detection and therapeutic stratification; however, their complex patterns necessitates advanced analytical tools. Recent advances in artificial intelligence (AI) and machine learning (ML), including deep learning networks and graph-based models, have revolutionized cancer epigenomics by enabling rapid, high-resolution analysis of DNA methylation profiles. Moreover, these technologies are accelerating the development of Multi-Cancer Early Detection (MCED) tests, such as GRAIL’s Galleri and CancerSEEK, which improve diagnostic accuracy across diverse cancer types. In this review, we explore the synergy between AI and DNA methylation profiling to advance precision oncology. We first examine the role of DNA methylation as a biomarker in cancer, followed by an overview of DNA profiling technologies. We then assess how AI-driven approaches transform clinical practice by enabling early detection and accurate classification. Despite their promise, challenges remain, including limited sensitivity for early-stage cancers, the black-box nature of many AI algorithms, and the need for validation across diverse populations to ensure equitable implementation. Future directions include integrating multi-omics data, developing explainable AI frameworks, and addressing ethical concerns, such as data privacy and algorithmic bias. By overcoming these gaps, AI-powered epigenetic diagnostics can enable earlier detection, more effective treatments, and improved patient outcomes, globally. In summary, this review synthesizes current advancements in the field and envisions a future where AI and epigenomics converge to redefine cancer diagnostics and therapy.